India’s generic drugmakers are not going to take it anymore. BusinessWorld reports that the Indian Pharmaceutical Alliance has hired the Washington, DC, strategy group India First LLC to promote the value of the country’s generic drugs.
India First said in a statement that it will take on Big Pharma lobbying forces, such as PhRMA and the National Association of Manufacturers which “downgrade the reputation of Indian pharmaceuticals in order to maintain marketshare and destroy competition.”
India’s generics industry can be lightly described as troubled. The US has banned drugs from four Ranbaxy pharmaceutical sites over manufacturing site integrity. Parent company Sun Pharmaceuticals has been similarly pinched, for reasons including file destruction and hiding unfavorable data.
